COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.

Cencora, Inc. earns a Buy rating with a $337 fair value. Learn how its specialty drug focus and strategic investments drive ...

Healthcare distributor Cencora (NYSE:COR) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Q3 2025 Earnings Call Transcript August 6, 2025 Cencora, Inc. beats earnings expectations. Reported EPS is $4, expectations were $3.85. Operator: Hello, everyone, and thank you for joining the Cencora ...

Cencora, Inc. ( NYSE: COR) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F. Cleary - Executive VP & CFO Robert P ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped ...

This was the stock's third consecutive day of losses.

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

Bloomberg's large-cap BMVP portfolio delivered positive returns in 2Q but trailed its benchmarks, held back by its defensive tilt during one of the fastest market rebounds on record.

CONSHOHOCKEN, Pa. - On Wednesday, Cencora, Inc. (NYSE: COR) reported third-quarter fiscal 2025 results that exceeded analyst expectations, with adjusted earnings per share of $4.00 beating the ...

Cencora, Inc. (NYSE:COR) is an American pharmaceutical and healthcare services provider. It is a rare stock in its peers that is in the green this year. Cencora, Inc.